A plant under stress
Resveratrol is among the compounds plants produce when injured or infected. This gave rise to the idea that plant stress signals might also activate human protective programmes.
AFEGA Research GroupSubstance profile 01 · Trans-Resveratrol
Resveratrol
A plant compound between herbal tradition and modern longevity research.
Red wine, plant stress responses, sirtuins, calorie restriction and personal experience: few natural compounds bring together so many ideas about healthy ageing. This profile tells the story of where these ideas come from, which effects people associate with resveratrol and what experiences they describe.
Why resveratrol fascinates
Four stories shaped today’s picture.
Tradition, epidemiological observation, laboratory research and personal practice have become intertwined over decades.
The French Paradox
The observation that wine was associated with heart health despite its alcohol content gave the compound a culturally resonant story: the hoped-for benefits of red wine without the alcohol.
Sirtuins and calorie restriction
Model-based studies linked resveratrol with lifespan, energy signalling and calorie restriction. A plant compound thus became a symbol of modern longevity research.
People try it for themselves
Early self-users, prominent researchers and biohacking communities developed their own routines and shared their observations and interpretations.
The story of the whole plant
Hu Zhang in Chinese herbal medicine
Hu Zhang is the root or rhizome of Japanese knotweed. In Chinese herbal medicine, the herbal material is associated with moving the blood and resolving stasis; traditional uses also include cough, jaundice, inflammation and injuries. The unit of this tradition is the whole herbal material, with the interplay of its various constituents.
Japanese knotweed in Western herbalism
In Western herbalism, the plant gained a new role particularly through Stephen Harrod Buhner’s book Healing Lyme . There it became a central component of a multi-herb protocol. Users and herbal practitioners associate it with tissue penetration, circulation, regulation of inflammation, neurological complaints and synergy with other herbs.
The plant matrix as a model of action
In this view, resveratrol is a familiar constituent and an important explanatory element, but not the sole agent responsible for the effect. Accompanying compounds, the plant matrix and combinations are part of the model. Books, herbal monographs and patient forums thus gave rise to a distinct experiential tradition alongside the use of isolated trans-resveratrol.
Attributed effects
What people associate with resveratrol.
Each card begins with the proposed effect, its origins and — where documented — experiences. Clicking “What is the current state of research?” takes you to an overview of current research.
01
Live longer and stay healthy for as long as possible
The proposed effect
Few ideas are as closely associated with resveratrol as the desire to influence ageing processes favourably. In longevity circles, many see the compound as a companion for a long, vital life — not just for additional years, but for health and function preserved for as long as possible.
Where it comes from
This idea grew out of several strands: lifespan findings in model organisms, sirtuin research, similarities to calorie restriction and the idea of xenohormesis. According to this hypothesis, plant stress compounds can give other organisms early warning of a more challenging environment ahead — thereby triggering their own protective programmes.
Experience and meaning
Early self-users described taking it as a conscious decision in the face of the inevitable progression of ageing. Their accounts describe more energy, mental presence and a sense of actively supporting their own long-term health.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 45 %
Mainly model organisms and mechanistic studies; interesting experiments, but limited direct applicability to human lifespan. View the assessed studies →
What is the current state of research?
The current state of research
The original findings are scientifically real and important for ageing research. Lifespan extensions were first observed in yeast and other model organisms. In mice on a high-calorie diet, health and survival improved; normally fed mice did not live longer in a key study. In humans, studies showing an extended lifespan or a validated slowing of biological ageing are still lacking. Human studies have also failed to confirm a reliable overall effect on SIRT1. The idea of geroprotection therefore remains an interesting research hypothesis, but one not yet clinically confirmed.
02
Metabolism, blood glucose and weight
The proposed effect
Resveratrol is often associated with metabolic flexibility: more stable blood glucose, a better response to insulin and the body coping more easily with excess energy. This includes the idea that resveratrol might mimic effects of calorie restriction and support metabolism during a very high-calorie diet.
Where it comes from
This idea connects animal models on high-calorie diets with human studies of insulin sensitivity, HOMA-IR, mitochondrial parameters and other metabolic markers. Calorie restriction and the regulation of energy signalling thereby became central themes in the resveratrol story.
Experience and meaning
Users often focus on energy, appetite, weight and glucose readings they measure themselves. They report a more even sense of energy, a steadier response to meals and changes that can be observed directly in everyday life.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 45 %
Small, short, positive human studies with many surrogate endpoints and differing populations. View the assessed studies →
What is the current state of research?
The current state of research
Some small studies in people with obesity or type-2 diabetes found changes in individual glucose and insulin markers. Other well-controlled studies found no comparable additional benefit. Populations, doses, duration and baseline treatment differ substantially. There is currently no robust clinical evidence for healthy people or for reliable weight reduction. Baseline circumstances and individual responses may still play a role; no validated rules for identifying responders are yet available.
03
Heart, blood vessels and circulation
The proposed effect
Many people know resveratrol through red wine. It is thought to provide some of the cardiovascular benefits associated with the “French Paradox” — in concentrated form and without alcohol. There is also the idea that resveratrol supports blood vessels, circulation and healthy platelet function.
Where it comes from
Different stories converge here: epidemiological observations about wine, the identification of resveratrol in wine, laboratory work on LDL oxidation and traditional concepts of circulation around Hu Zhang. In popular accounts, they merged into an accessible story of heart protection.
Experience and meaning
The idea brings together cultural experiences with wine, the language of circulation in herbal medicine and modern vascular research. Users therefore associate resveratrol with heart health, good circulation and the desire to support blood vessels over the long term.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 55 %
Controlled studies show FMD signals, but are small and mainly examine short-term surrogate measures. View the assessed studies →
What is the current state of research?
The current state of research
The French Paradox cannot reliably be attributed to a single constituent of wine. Human studies do, however, provide interesting signals: some report improved flow-mediated dilation, a marker of endothelial function. Effects on blood pressure are smaller and inconsistent. It has not yet been convincingly shown that this leads to fewer heart attacks, strokes or other events in the long term. The vascular hypothesis thus has biological and some experimental human support, while its long-term clinical benefit remains unresolved.
04
Antioxidant protection, inflammation and stress resistance
The proposed effect
Resveratrol is regarded as a powerful antioxidant and a compound that can engage the body’s own stress-response and protective systems. Anti-inflammatory properties, protection from oxidative stress and support for cellular defences and DNA repair are attributed to it.
Where it comes from
Part of this idea follows the traditional antioxidant concept. Another part is subtler: resveratrol might act less as a chemical “free-radical scavenger” and more as a signal activating adaptive stress responses. Xenohormesis and hormesis give this view an evolutionary framework.
Experience and meaning
For many users, the appeal lies precisely in this systems-level idea: not treating a single symptom, but supporting the organism’s ability to cope with challenges. This expectation is broader than any individual laboratory value.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 45 %
Mechanistic and biomarker studies are numerous, but often small, exploratory and only indirectly relevant clinically. View the assessed studies →
What is the current state of research?
The current state of research
In cell and animal models, resveratrol influences numerous redox, inflammatory and stress pathways, including NF-κB, Nrf2, AMPK, mTOR and autophagy. In human studies, individual inflammatory markers change, but not consistently. Biological effects are therefore plausible; what remains unclear is which signalling changes become clinically meaningful at usual exposures. An altered biomarker alone does not answer this question.
05
Memory, cerebral blood flow and mental agility
The proposed effect
Resveratrol is associated with memory, mental performance and protection of ageing nerve cells. Some people are interested in it not because of a specific illness, but because they wish to remain mentally present and agile.
Where it comes from
Research into neuroprotective mechanisms met human studies of memory tasks, functional connectivity and cerebrovascular parameters. This developed into a broader story about brain health and healthy ageing.
Experience and meaning
Early self-user forums contain reports about focus, mood and mental presence. Resveratrol is often described there as part of a personal strategy for maintaining mental agility and alertness in everyday life.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 40 %
A few small human studies with selected positive measures of memory, blood flow or connectivity. View the assessed studies →
What is the current state of research?
The current state of research
Small human studies found individual positive signals in memory measures, functional connectivity or cerebral blood flow. Systematic analyses have so far shown no consistent general improvement in cognitive performance in healthy adults. Studies in Alzheimer’s disease are too small and inconsistent to support robust claims about prevention or treatment. Selective signals justify further research, but currently do not allow reliable predictions for an individual.
Sources for the current assessmentWitte 2014 ↗Cognition meta-analysis 2018 ↗Alzheimer’s review 2022 ↗
06
Mitochondria, energy and physical performance
The proposed effect
Resveratrol research gave rise to the image of an “exercise pill”: a compound that activates mitochondrial programmes, supports endurance and mimics some adaptations to training. Many users also associate resveratrol with energy and physical resilience.
Where it comes from
Particularly influential were mice that ran longer on a treadmill after receiving resveratrol and showed changes in mitochondrial signalling pathways. The media and longevity communication quickly translated this striking image into an expectation of improved human performance.
Experience and meaning
Early self-experimentation groups described more energy, focus and endurance. Highly individual routines developed, with close attention to timing, combinations and personal physical responses.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 45 %
Strong preclinical plausibility, but limited direct testing in humans and selective performance or biomarker findings. View the assessed studies →
What is the current state of research?
The current state of research
The mitochondrial findings in animals are well documented, but cannot be directly transferred to human training performance. Human studies present a mixed picture. In a randomised study of older men, 250 mg daily attenuated several beneficial adaptations to endurance training; other small studies examined different populations and endpoints. Whether resveratrol helps or interferes under particular conditions remains unresolved. It has not been confirmed as a general training enhancer.
07
Postmenopausal women, bones and liver
The proposed effect
As the number of human studies grew, resveratrol also attracted interest for more specific circumstances: for postmenopausal women, for maintaining bone health and for people wishing to support their liver and metabolic health.
Where it comes from
Study populations became new target groups. Measurements of bone mineral density, cerebrovascular parameters and individual liver markers each generated their own narratives. They illustrate how a widely discussed compound moves into increasingly specific areas of use.
Experience and meaning
For postmenopausal women and people focused on bone or liver health, changes in wellbeing and personally monitored measurements can be particularly meaningful. Here, resveratrol is understood as part of a longer-term strategy for healthy ageing.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 45 %
Positive signals concern selected measurement sites, biomarkers and narrowly defined populations; patient-relevant endpoints are lacking. View the assessed studies →
What is the current state of research?
The current state of research
In postmenopausal women, selected positive signals concern bone mineral density, cognition and cerebrovascular parameters. A reduction in fractures has not been shown. In non-alcoholic fatty liver disease, studies and meta-analyses are contradictory; a consistent overall benefit has not yet been confirmed. Findings remain specific to populations, doses and endpoints and are not yet suitable for general promises to target groups.
08
Cancer research and chemoprevention
The proposed effect
Since a widely discussed publication in 1997, resveratrol has been associated with the idea that it could influence the onset and development of cancer. In natural-compound research, it thus became an important example of chemoprevention, cellular protection and support for healthy ageing processes.
Where it comes from
The original study examined initiation, promotion and progression in research models. Its wide impact made resveratrol a symbol of natural-compound chemoprevention and opened up numerous research programmes on the cell cycle, apoptosis, inflammation and tissue exposure.
Experience and meaning
For many people, the desire to support the body’s own defences against cancer carries particular weight. In this story, resveratrol represents the idea that a plant compound can engage several cellular protective pathways at once.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 50 %
Extensive cell and animal research with substantial mechanistic detail, but very limited direct clinical applicability. View the assessed studies →
What is the current state of research?
The current state of research
Anticancer research is extensive, but mainly concerns cell and animal models. Clinical studies have primarily examined pharmacokinetics, tissue exposure, biomarkers or feasibility. A benefit for cancer prevention, tumour control, survival or quality of life has not yet been robustly confirmed. Resveratrol is therefore not a substitute for oncological diagnosis, prevention or treatment; combinations with cancer treatment require medical or oncological supervision because of possible interactions.
Sources for the current assessmentSRT501 study 2012 ↗
Personal experience
People experience resveratrol in their own way.
Personal accounts show what users pay attention to: energy and focus, metabolism and glucose, physical resilience, mood and their personal sense of health. Many develop a consciously monitored, individual practice from this.
Record observations
Personal changes become clearer when timing, the routine of use and the observed effect are recorded.
Recognise personal patterns
Recurring observations can reveal which aspects are particularly meaningful to the individual.
Share experiences
Self-user forums, books and personal conversations have played an important role in making the varied experiences with resveratrol visible.
Absorption & metabolism
Well absorbed — and rapidly transformed.
After oral intake, a large proportion of resveratrol crosses the intestinal barrier. The intestine and liver, however, rapidly convert it into sulphate and glucuronide metabolites.
The low concentration of the unchanged parent compound is therefore not the end of the story. Metabolites, local release in tissues, the microbiome and hormetic signalling are serious research questions. Which of these pathways contributes to clinically meaningful effects in humans remains unresolved.
Open human pharmacokinetics ↗Resveratrol is absorbed relatively well from the intestine.
Sulphate and glucuronide metabolites form early and in large amounts.
The parent compound, metabolites, tissue release and microbiome are studied together.
Whether higher exposure also increases health benefit must be demonstrated clinically in each case.
Safety & interactions
An informed decision also requires knowing the limits.
These points are safety information, not a recommendation for consumption. In the presence of medication or illness, personal experience and scientific interest do not replace individual medical assessment.
The regulatory framework
150 mg daily: assessed maximum amount, not an efficacy dose.
EFSA identified no safety concerns for synthetic trans-resveratrol at up to 150 mg per day for adults under the conditions assessed. The figure applies to that assessed context of use.
Stomach and intestine
Diarrhoea, abdominal pain, nausea and flatulence are dose-dependent and become more frequent at gram-level doses.
Medication
Resveratrol can affect CYP enzymes. Under the EU requirement, people taking medication should consume it only under medical supervision.
Bleeding and surgery
Medical assessment is advisable when taking anticoagulants or antiplatelet drugs, in the presence of a bleeding tendency or before planned procedures.
Insufficiently studied
Children, adolescents, pregnancy and breastfeeding are not covered by the assessed context of use; intake is not recommended in these groups or circumstances.
Regulatory context
Research, use and advertising are different questions.
Novel food framework
The EU Union list includes trans-resveratrol for adult food supplements at a maximum of 150 mg per day, with a specific medication warning.
No blanket authorisation of claims
A scientific or historical description of an effect does not automatically make it a permissible advertising claim in the context of an offer for sale.
Tell the story, identify its origins, assess it
We show which ideas and experiences exist, where they come from and how far scientific support currently extends.
Study-specific claims
How likely is each narrowly defined statement to be true?
Each percentage refers exclusively to the claim written beside it. The assessment is not whether a substance “works overall”, but how plausible the specific statement is in light of the study, counterfindings and applicability.
Two different measures: the small bars in the effect cards assess the strength of two evidence bases. The detailed percentages below instead assess the probability of each specifically formulated claim. Study quality is an important basis for this, but is not equivalent to truth.
Howitz et al. 2003approx. 75 %
Resveratrol extends lifespan under the yeast-model conditions used.
Estimated probability that this claim is true: approx. 75 %
Rationale: Experimental model finding; later work qualifies, in particular, the claimed direct activation of SIRT1 and the applicability to humans.
Baur et al. 2006approx. 90 %
Resveratrol improves survival and selected metabolic parameters in mice on a high-calorie diet.
Estimated probability that this claim is true: approx. 90 %
Rationale: Controlled animal-model finding in a clearly delimited population; no direct conclusion about normally nourished humans.
Pearson et al. 2008approx. 90 %
Resveratrol does not extend lifespan in normally fed mice under the conditions tested.
Estimated probability that this claim is true: approx. 90 %
Rationale: Robust null finding in an animal model; it contradicts a general claim of lifespan extension, but does not rule out other endpoints.
Timmers et al. 2011approx. 65 %
150 mg of resveratrol daily changes selected metabolic and mitochondrial measurements in men with obesity within 30 days.
Estimated probability that this claim is true: approx. 65 %
Rationale: Randomised crossover design, but only eleven participants, short duration and numerous predominantly surrogate endpoints.
Brasnyó et al. 2011approx. 50 %
10 mg of resveratrol daily improves insulin sensitivity in people with type-2 diabetes within four weeks.
Estimated probability that this claim is true: approx. 50 %
Rationale: Small, short study with a positive surrogate finding; the human literature on metabolic effects is inconsistent overall.
Poulsen et al. 2013approx. 75 %
1.500 mg of resveratrol daily provides no clinically relevant general metabolic benefit in men with obesity after four weeks.
Estimated probability that this claim is true: approx. 75 %
Rationale: Placebo-controlled null finding; duration and population limit the statement to this setting.
Witte et al. 2014approx. 55 %
200 mg of resveratrol daily improves selected memory scores in older adults with overweight after 26 weeks.
Estimated probability that this claim is true: approx. 55 %
Rationale: Randomised study with selective positive endpoints; the small sample and lack of robust independent replication limit confidence.
Farzaei et al. 2018approx. 35 %
Resveratrol produces a general, clinically meaningful improvement in human cognitive performance.
Estimated probability that this claim is true: approx. 35 %
Rationale: The studies synthesised are small and heterogeneous; consistent benefits across cognitive domains and populations are lacking.
Gliemann et al. 2013approx. 65 %
Resveratrol may attenuate selected beneficial vascular adaptations to endurance training in older men.
Estimated probability that this claim is true: approx. 65 %
Rationale: Randomised controlled study with an unexpected counterfinding; the small sample and individual endpoints limit generalisation.
Olesen et al. 2014approx. 70 %
Resveratrol does not reliably enhance training-induced improvements in muscle metabolic function in older men.
Estimated probability that this claim is true: approx. 70 %
Rationale: Controlled human finding without the expected additional benefit; small sample and specific population.
Wong et al. 2013approx. 70 %
Resveratrol may increase flow-mediated dilation in adults with obesity.
Estimated probability that this claim is true: approx. 70 %
Rationale: Controlled surrogate signal; small study, no conclusion about long-term cardiovascular events.
Bo et al. 2016approx. 60 %
Resveratrol reduces selected inflammatory markers in the short term in healthy smokers.
Estimated probability that this claim is true: approx. 60 %
Rationale: Controlled signal in a specific population; biomarkers do not establish a clinical benefit for inflammation.
NAFLD meta-analysis 2020approx. 25 %
Resveratrol improves clinically relevant liver outcomes in non-alcoholic fatty liver disease.
Estimated probability that this claim is true: approx. 25 %
Rationale: Small, heterogeneous studies do not show consistent improvement in key liver or metabolic endpoints.
Popat et al. 2013approx. 10 %
High-dose resveratrol provides a clinically favourable benefit in previously treated multiple myeloma.
Estimated probability that this claim is true: approx. 10 %
Rationale: SRT501 development was discontinued after serious renal events; small, highly selected patient population and no evidence of efficacy.
Walle et al. 2004approx. 90 %
Orally ingested resveratrol is absorbed, but rapid metabolism results in only very low exposure to the unchanged parent compound.
Estimated probability that this claim is true: approx. 90 %
Rationale: Direct human pharmacokinetics; small study, but consistent with the known rapid metabolism.
RESHAW 2020 — extrapolation to fracturesCannot be reliably quantified
The changes in individual bone-density measurements observed in RESHAW reduce fracture risk.
Estimated probability that this claim is true: cannot be reliably quantified
Rationale: The study was not designed to assess fractures reliably. Bone density is a surrogate measure and does not allow robust quantitative extrapolation here.
Important: “not independently supported” does not mean “disproved”. Conversely, a lack of disproof is not evidence of efficacy. Substance form, dose, population, duration and endpoint limit every statement.
Sources & transparency
The history of proposed effects and the current state of research have their own sources.
This profile combines a documentary reconstruction of 42 effect claims, 58 shifts in meaning and 19 lines of transmission with a separate assessment of the current state of research. The effect cards therefore deliberately separate sources on origins and experience from the sources supporting the current overall assessment.
Transparency notice
The AFEGA Anti-Aging-Shop, operated separately from the AFEGA Research Group, also sells resveratrol products. The current state of research is assessed independently of product interests.
AFEGA’s perspective
Resveratrol brings together herbal tradition, modern longevity research and personal experience. It is precisely this interplay that makes its story so multifaceted.Go to the substance library →